CONTENTS 目錄 華潤醫療控股有限公司 二零二四年度報告 1 2 Corporate Information 公司資料 6 Chairman's Statement 董事長報告 10 Management Discussion and Analysis 管理層討論與分析 24 Directors' Report 董事會報告 66 Corporate Governance Report 企業管治報告 93 Directors and Senior Management 董事及高級管理人員 102 Independent Auditor's Report 獨立核數師報告 110 Consolidated Statement of Profit or Loss 綜合損益報表 111 Consolidated Statement of Comprehensive Income 綜合全面收益報表 112 Consolidated Statement of Financial Position 綜合財務狀況報表 115 Consolidated Statement of Changes in Equity 綜合權益 ...

智通财经APP获悉，中金发布研报称，考虑华润医疗(01515)住院和门诊次均收入下降，下调2025年净利 润20.8%至5.66亿元，同比持平，引入2026年净利润5.92亿元，同比增加4.5%。基于对公司通过加强学 科建设提升区域影响力的看好，维持跑赢行业评级和目标价5.0港元，对应2025/2026年10.8/10.2倍市盈 率，对应23.2%上行空间。 截至2024年底，公司在中国10个省、市共管理运营105家医疗机构(三级医院13个，二级医院22个，一级 医院及社区中心41个，诊所及其他医疗机构29个)，公司自有医院运营床位数合计18,567张，床位使用 率为82.9%。2024年，公司自有医院常规门诊量和住院量分别为1032.56万人次和56.01万人次。 医院业务方面，2024年门诊和住院人次同比保持增长 2024年，公司医院业务收入人民币91.85亿元，同比下滑2.4%;其中，门诊人次增加1.3%，住院人次增加 1.0%;门诊服务收入人民币36.65亿元，同比下滑1.0%，住院服务收入人民币52.94亿元，同比下滑 3.3%，主要受医保控费影响门诊和住院次均收入同比略下滑。2024年，医院毛利为 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 截 至2024年12月31日 止 年 度 全 年 業 績 公 告 | 財 | 務 | 摘 | 要 | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | | | | | | | 2024年 | 2023年 | | 收 | | 益（人 | 民 | 幣 | 千 | | 元） | | | | | | | ...

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company's overall performance in H1 2024 met expectations, with improved profitability [1] - Despite a slight decline in revenue, the company's profit optimization is promising [1] - The company is expected to see continuous growth in business scale and profitability due to asset integration and refined management [3] Financial Performance - H1 2024 revenue was RMB 49.76 billion, a decrease of 2.7% YoY, while net profit increased by 9.0% to RMB 4.34 billion [4] - Hospital business revenue in H1 2024 was RMB 46.00 billion, a slight decrease of 3.0% YoY, with outpatient revenue increasing by 1.7% and inpatient revenue decreasing by 6.1% [4] - Other business revenue increased by 1.8% to RMB 3.76 billion [4] Operational Highlights - The company managed 127 medical institutions across 10 provinces in China, including 13 tertiary hospitals and 23 secondary hospitals [4] - In H1 2024, outpatient visits and inpatient admissions at self-owned hospitals increased by 3.5% and 3.0% YoY, reaching 5.05 million and 280,000 respectively [1] - Average revenue per outpatient visit and inpatient admission decreased by 2.0% and 8.8% respectively, influenced by a two-year gap in medical insurance settlements [1] Profitability and Cost Efficiency - The gross profit margin for the hospital business in H1 2024 was 20.1%, with a gross profit of RMB 9.23 billion [2] - Financial expenses decreased by 34.8% to RMB 39.84 million due to the replacement of foreign loans with RMB loans, resulting in lower interest rates [2] - Income tax decreased by 16.3% to RMB 116 million, primarily due to a reduction in taxable income within China [2] Future Projections - The company's revenue for 2024-2026 is projected to be RMB 105.20 billion, RMB 110.84 billion, and RMB 117.46 billion, with YoY growth rates of 4.08%, 5.37%, and 5.97% respectively [3] - Net profit attributable to shareholders is expected to be RMB 7.44 billion, RMB 7.82 billion, and RMB 8.17 billion for 2024-2026, with YoY growth rates of 188.90%, 5.02%, and 4.50% respectively [3] Market Position - The company is a leading comprehensive medical group under the central state-owned enterprise, with significant growth potential in the healthcare sector [3]

Investment Rating - The investment rating for the company is "Buy" with a target price of 5.98 HKD per share, compared to the current price of 3.52 HKD [2][12]. Core Insights - The company reported a slight decline in revenue for the first half of 2024, with a year-on-year decrease of 2.7% to 4.98 billion RMB, primarily due to the impact of two years of medical insurance settlement differences and a high base from the first half of 2023. However, net profit attributable to shareholders increased by 9.1% to 434 million RMB [6][12]. - The hospital business revenue also saw a slight decline, with outpatient and inpatient visits increasing, but average revenue per visit decreased. The medical business revenue for the hospitals was 4.60 billion RMB, down 3.0% year-on-year. Excluding the impact of medical insurance settlement differences and the closure of Huaiyin Hospital, revenue remained stable [6][12]. - The company is expected to continue its cost reduction and efficiency improvement strategies, which are anticipated to mitigate the impact of medical insurance settlement differences. For 2024, the company forecasts a stable growth in internal performance, with net profit expected to increase by 8.6% compared to the adjusted figure from 2023 [6][12]. Summary by Sections Financial Performance - For the first half of 2024, the company achieved an EBITDA of 970 million RMB, remaining stable year-on-year. The proportion of drug and consumable costs in revenue decreased by 0.6 percentage points, helping to offset the impact of medical insurance settlement differences [6][12]. - The forecast for 2024 indicates a slight decline in hospital business revenue, with expectations of a 4-5% growth in 2025-2026 as the impact of medical insurance settlement differences diminishes [12][13]. Hospital Operations - The company operates a total of 127 medical institutions, including 13 tertiary hospitals and 23 secondary hospitals, with a total of 20,845 operational beds as of June 30, 2024. The company is focusing on enhancing the quality and efficiency of its operations through centralized procurement and digitalization [6][12]. - The outpatient revenue was 1.81 billion RMB, up 1.4% year-on-year, while inpatient revenue was 2.70 billion RMB, down 6.1%. The average revenue per outpatient visit decreased by 2.0%, and for inpatient visits, it decreased by 8.8% [6][12]. Profitability and Valuation - The company is expected to maintain a profit margin improvement trend, with net profit projected to grow by approximately 7% in 2025-2026. The reference valuation based on comparable companies suggests a PE ratio of 10 times for 2024, leading to a reasonable value of 5.98 HKD per share [12][13].

China Resources Medical Holdings Company Limited |Incorporated in the Cayman Islands with limited liability) (於同曼群島註冊成立之有限責任公 司) Stock Code 股票代號 : 1515 0 w INTERIM REPORT 中期報告 2024 CONTENTS 目錄 CONTENTS 目錄 CONTENTS 目錄 2 Corporate Information 公司資料 5 Management Discussion and Analysis 管理層討論與分析 27 Corporate Governance Highlights 企業管治摘要 29 Other Information 其他資料 38 Review Report 審閱報告 40 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 中期簡明綜合損益及其他全面收益報表 42 Interim Condense ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 1 China Resources Medical Holdings Company Limited 華潤醫療控股有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 截至2024年6月30日止六個月之中期業績公告 華潤醫療控股有限公司（「本公司」）董事會（「董事會」）欣然宣佈，本公司及其附屬公 司（「本集團」）截至2024年6月30日止六個月（「報告期」）之未經審核綜合業績，如下： 中期簡明綜合損益及其他全面收益報表 截至2024年6月30日止六個月－未經審核 | --- | --- | --- | --- | |----------------------|-------|-------------------------|-----------------------| | | | 截至 6 月 30 \n2024 年 | 日止六個月 \n2023 年 | | | 附註 | 人民幣 ...

Leadership Appointments - Mr. YU Hai was appointed as an executive Director and the chief executive officer of the Company effective from February 27, 2023[4] - Ms. YANG Min was appointed as an executive Director and the Chief Financial Officer effective from June 13, 2023[5] - Mr. ZHOU Peng was appointed as an independent non-executive Director and a member of the Audit Committee effective from September 14, 2023[5] Company Locations - The Company's headquarters and principal place of business in Chinese Mainland is located at 14/F, Kunlun Center Office Building, No. 9, Fuyi Street, Fengtai District, Beijing[6] - The Company's principal place of business in Hong Kong is located at Room 2603, 26/F, China Resources Building, 26 Harbour Road, Wanchai, HKSAR[7] - The Company's registered office is located at Harneys Fiduciary (Cayman) Limited, 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman, KY1-1002, Cayman Islands[7] Financial and Legal Advisors - The Company's Hong Kong branch share registrar is Computershare Hong Kong Investor Services Limited, Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, HKSAR[7] - The Company's auditors are KPMG, Certified Public Accountants, Public Interest Entity Auditor registered in accordance with the Accounting and Financial Reporting Council Ordinance, located at 8th Floor, Prince's Building, 10 Chater Road, Central, Hong Kong SAR[7] - The Company's legal adviser for Hong Kong law is Jingtian & Gongcheng LLP, located at Suites 3203–3207, 32/F, Edinburgh Tower, The Landmark, 15 Queen's Road Central, Central, HKSAR[8] - The Company's principal bankers include China Merchants Bank, located at 2nd Floor, Tower A, 156 Fuxingmennei Street, Xicheng District, Beijing, and Industrial and Commercial Bank of China, located at Room 102, Block 16, Court 2, East Baizhifang Street, Xicheng District, Beijing[9] Business Performance and Acquisitions - The Group completed the acquisitions of Liaojian and Jiangneng subsidiaries, significantly improving operational quality and performance, securing a favorable position in regional competition[12][13] - The Group's medical business recorded an increase in conventional outpatient visits exceeding 10 million, a year-on-year growth of 97%, and achieved operating revenue of RMB10.11 billion, a year-on-year increase of 79.8%[14] - The Group added 9 provincial key specialties, 31 municipal key specialties, and 67 new specialty clinics for specific diseases during the Reporting Period[14] - The Group initiated 37 national-level centralized projects and implemented 323 new technology projects[14] - The Group conducted 43 new drug clinical trial projects with Good-Clinical Practice (GCP) and obtained 14 patent authorizations[14] - The Group's R&D investment in 2023 grew by 206% year-on-year[14] - The Group's member hospitals achieved significant improvements in patient satisfaction through enhanced patient service management mechanisms[14] - The Group continues to focus on state-owned hospital reforms, aiming to improve medical technology levels and healthcare service efficiency through comprehensive innovation[14] - The Group's acquisitions of LH Subjects and JE Subject by the end of June 2023 further expanded its hospital network, laying a solid foundation for future high-quality development[17] - Consolidated revenue for the Reporting Period amounted to RMB10.108 billion, compared to RMB7.901 billion in FY2022 (restated)[21] - Consolidated net profit for the Reporting Period was RMB328 million, consistent with FY2022 (restated)[21] - LH Member Institutions and JE Member Medical Institutions contributed RMB4.096 billion in consolidated revenue and RMB383 million in consolidated net profit[21] - The Group operates a total of 134 medical institutions, including 13 Grade III hospitals, 25 Grade II hospitals, 43 Grade I hospitals and community centers, and 53 clinics and other medical institutions[23] - Self-owned hospitals recorded a year-on-year improvement in business volume, revenue, and operating profit during the Reporting Period[21] - The utilization rate of beds in self-owned hospitals increased to 83.7% in 2023 from 76.3% in 2022[24][25] - Revenue from medical business in self-owned hospitals reached RMB9.406 billion in 2023, up from RMB8.675 billion in 2022[24][25] - The Group completed the acquisition of LH Subjects and JE Subject in June 2023, expanding its hospital network[18] - The Group's financial results for the Reporting Period included the financial results of LH Subjects and JE Subject starting from January 1, 2023[20] - The Group's financial statements for FY2022 were restated to include the financial results of LH Subjects and JE Subject from June 2, 2022[19] - Hospital business revenue increased by 33.4% year-on-year to RMB 9,406.153 million, with outpatient revenue up 32.5% to RMB 3,932.694 million and inpatient revenue up 34.0% to RMB 5,473.459 million[28][30] - Hospital business segment profit rose 37.2% year-on-year to RMB 638 million, with LH and JE subjects contributing RMB 479 million and stock hospitals contributing RMB 159 million[33] - Excluding one-time impairment, stock hospitals' profit increased 47.4% year-on-year to RMB 484 million, driven by improved operational efficiency[33] - Other business revenue decreased 17.3% year-on-year to RMB 701 million, with segment profit down 6.8% to RMB 236 million[34] - Total revenue increased 27.9% year-on-year to RMB 10,107.5 million, with segment gross profit up 45.9% to RMB 1,905.837 million[28] - JR Holdings and JR Renkang achieved combined revenue of RMB 223 million and net profit of RMB 185 million, with the company's share of net profit at RMB 90.78 million[41] - The company received RMB 88.88 million in FY2022 dividends from JR Holdings and JR Renkang[41] - The company's investment in JR Holdings and JR Renkang totaled RMB 918 million and RMB 59.15 million, respectively, representing 7.2% of total assets[40] - The fair value of the company's investment in UMP Healthcare Holdings was approximately RMB 49.08 million as of December 31, 2023[44] - No concrete plans for material investment or capital asset acquisitions beyond ordinary business operations as of the report date[45] - The company's investment in United Medical Group has a fair value of approximately RMB 49.08 million as of December 31, 2023[46] - The Group achieved revenue of RMB 10.108 billion during the reporting period, a 27.9% year-on-year increase, with LH Subjects and JE Subject contributing RMB 4.096 billion[52] - Hospital business revenue reached RMB 9.406 billion, a 33.4% year-on-year increase, driven by increased patient visits and improved bed utilization[53] - Other business revenue decreased by 17.3% year-on-year to RMB 701 million[53] - Gross profit increased by 45.9% year-on-year to RMB 1.906 billion, with a gross profit margin of 18.9%[53] - Administrative expenses totaled RMB 971 million, a 20.0% year-on-year increase, with existing business administrative expenses growing at a lower rate of 3.3% due to effective cost control measures[54] - Impairment losses on goodwill, property, plant and equipment, and right-of-use assets amounted to RMB 141 million, RMB 209 million, and RMB 2 million, respectively, primarily due to the underperformance of Huaiyin Hospital[55] - The company plans to continue building leading hospitals, accelerate the construction of provincial and municipal key specialties, and expand the GCP program to enhance medical education and research[49] - The company aims to deepen regional integrated management and regional medical consortium construction to achieve comprehensive management of leading hospitals over regional medical institutions[50] - The company will strengthen the brain specialty, promote the construction of brain hospitals in Guangxi, and further expand the discipline's capacity in South China[50] - Huaiyin Hospital's revenue decreased by over 60% year-on-year, with an operating loss exceeding RMB 30 million in 2023[56] - The carrying amount of government service fee receivable for Huaiyin Hospital was RMB 73 million, and the loan receivable was RMB 41 million as of December 31, 2022[58] - The Group recorded impairment losses of RMB 114 million related to Huaiyin Hospital, reducing pre-tax profit by RMB 466 million and net profit by RMB 447 million[58] - The Group's income tax expense increased by 74.3% year-on-year to RMB 165 million, primarily due to increased profit[58] - The Group's net profit was RMB 328 million, representing a year-on-year decrease of 0.1%, with Huaiyin Hospital's impairment reducing net profit by RMB 447 million[58] - The Group's consolidated bank balances and cash, certificate of deposit, and bank financial products amounted to approximately RMB 1.28 billion as of December 31, 2023[59] - The Group obtained an offshore revolving term loan facility of HK$3.7 billion and mainland facilities of RMB 5.27 billion, with bank borrowings of RMB 2.16 billion as of December 31, 2023[60] - The Group's gearing ratio was 15.8% as of December 31, 2023, based on interest-bearing liabilities divided by total assets[62] - The Group is exposed to foreign currency risk, primarily related to fluctuations in the Hong Kong dollar and U.S. dollar against RMB, and has not used derivative contracts to hedge against this risk[63] - The Group had a total of 20,172 full-time employees as of December 31, 2023, a decrease from 20,622 employees in 2022[69] - Staff costs for FY2023 were approximately RMB3,406 million, up from RMB2,635 million in FY2022[69] - The Group operates a defined contribution Mandatory Provident Fund (MPF) Scheme in Hong Kong, with contributions based on a percentage of employees' basic salaries[70] - Subsidiaries in Mainland China participate in a central pension scheme, contributing a certain percentage of payroll costs[73] - The Group did not have any contingent liabilities or material pledges of assets as of December 31, 2023[66][67] - No significant subsequent events occurred after December 31, 2023, that would materially impact the Group's performance or value[68] - The Group faces foreign exchange risk due to currency fluctuations, primarily involving HKD and USD against RMB, but does not use derivative contracts to hedge this risk[65] - The Group is actively addressing talent shortages by attracting, training, and retaining qualified medical and management personnel to mitigate potential impacts on hospital operations[64][65] - The Group has implemented the "Hazardous Substances Safety Management Plan" and "Medical Waste Management System" to manage hazardous chemicals and medical waste, including storage, labeling, and disposal[85] - The Group formulated the "Energy Conservation, Emission Reduction and Environmental Protection Management System" to guide hospitals in energy conservation and eco-environmental protection, promoting green and high-quality development[85] - The Group monitors the implementation of environmental policies quarterly to ensure effective execution[85] - The Group has established the "Radiation Safety Management Plan" and "Radiation Emergency Plan" to manage radiation safety, with annual monitoring of radiation levels in hospitals[87] - The Group conducts regular drills and evaluations to assess responsiveness to radiation-related emergencies[87] - The Group maintains a high standard of health and safety measures in all company activities, with a focus on workplace safety[92] - The Group offers training and leadership development programs for employees with different academic backgrounds to support talent acquisition and continuous development[92] - The Group uses new media platforms to collect patient feedback and identify areas for service improvement[93] - The Group conducts annual supplier performance reviews and communicates with underperforming suppliers for rectification or improvements[94] - The Group's financial results for the year ended December 31, 2023, are detailed in the consolidated statement of profit or loss and comprehensive income[96] - The company proposes a final dividend of RMB6 cents per share for FY2023, totaling approximately RMB77.80 million, compared to RMB3.3 cents per share in FY2022[97][98] - The company's share premium as of December 31, 2023, amounted to RMB5,572,218,000, available for distribution subject to a solvency test[106] - Sales to the company's five largest customers accounted for approximately 6.5% of total sales in FY2023, with the largest customer contributing 3.0%[114] - Purchases from the company's five largest suppliers accounted for approximately 15.7% of total purchases in FY2023, with the largest supplier contributing 4.6%[114] - The company's dividend policy allows for profit sharing with shareholders in the form of annual dividends, provided it does not affect normal operations[100][104] - Sales to the top five customers accounted for approximately 6.5% of total sales for the year ended December 31, 2023, compared to 2.9% in 2022 (restated)[117] - Sales to the largest customer accounted for approximately 3.0% of total sales for the year ended December 31, 2023, compared to 1.2% in 2022 (restated)[117] - Purchases from the top five suppliers accounted for approximately 15.7% of total purchases for the year ended December 31, 2023, compared to 17.4% in 2022 (restated)[117] - Purchases from the largest supplier accounted for approximately 4.6% of total purchases for the year ended December 31, 2023, compared to 5.4% in 2022 (restated)[117] - The company maintains a directors' liability insurance policy to cover potential legal liabilities and related expenses for directors[116][118] - Independent non-executive directors receive an annual fee of HK$300,000 each[125] - The company has received annual independence confirmation from all independent non-executive directors, confirming their independence under Rule 3.13 of the Listing Rules[128][131] - None of the directors or their close associates had engaged in or had any interest in any business competing with the company as of December 31, 2023[130][132] - Song Qing, the Chairman, holds a long position of 400,000 ordinary shares, representing approximately 0.03% of the total shareholding[134] - Ge Lu, a non-executive director, holds a long position of 66,000 ordinary shares, representing approximately 0.01% of the total shareholding[135] - The maximum number of shares that can be issued under the Share Option Scheme is 83,376,300, representing 10% of the company's issued share capital as of the listing date[146] - The Share Option Scheme expired on September 29, 2023, and no further options can be granted or shares issued under the scheme thereafter[146] - The total number of shares issued or to be issued upon exercise of options granted to any grantee in any 12-month period shall not exceed 1% of the total number of shares in issue[147] - The Share Option Scheme was valid for 10 years from September 30, 2013, and no further options will be granted after its expiration, but previously granted options remain valid and exercisable[145] - The offer period for granting options is 14 days from the date of offer, and the option is deemed granted upon receipt of the signed offer document and a remittance of HK$1.00[151] - There is no minimum holding period required before an option can be exercised, and the exercise period is determined by the Board, not exceeding 10 years from the vesting period start date[152] - No share options were granted, exercised, expired, cancelled, or lapsed during the year ended December 31, 2023, and the Share Option Scheme expired on September 29, 2023[157] - The Share Award Scheme allows the Board to grant up to 5% of the total issued shares (64,833,825 shares) as Award Shares, representing approximately 5.00% of the issued share capital as of the annual report date[161] - The maximum number of Award Shares that can be granted to each Selected Participant is 1% of the total issued shares (12,966,765 shares)[161] - Since the adoption of the Share Award Scheme, a total of 32,212,216 Award Shares have been granted, subject to vesting criteria and conditions, with no shares granted in FY2023[164] - The Board has the discretion to determine the Grant Price for Award Shares, considering factors such as the participant's position, experience, years of service, performance, and contribution[160] - The Share Award Scheme is valid for 10 years from July 7, 2014, and is administered by the Board and the scheme's trustee[158] - 50% of the Relevant Award Shares were acquired by the Selected Participants at HK$5.27 per Share, and the remaining 50% were granted by the Company at zero consideration[166] - The Relevant Award Shares were vested during the period from FY2020 to FY2022, with the first batch vested on the date of the 2019 annual assessment, the second batch on the 2020 assessment, and the third batch on the 2021 assessment[166] - As of December 31, 2023, China Resources Company Limited held 474,319,516 shares, representing 36.58% of the issued share capital[171] - Mitsubishi UFJ Financial Group, Inc. held 65,224,166 shares, representing 5.03% of the issued share capital[171] - The remaining life of the Share Award Scheme is approximately 2 months as of the date of the annual report[167] - CR Hospital Investment acquired 76.10% equity interests in Liaoning CR Healthcare and 100% equity interests in Shenzhen CR Healthcare for RMB 3,394,607,000[177][178] - CR Hospital Investment also acquired 80% equity interests in the JE Subject for RMB 244,536,000 and purchased debts owed by the JE Subject amounting to RMB 316,944,600[179][182] - The equity transfers of the LH and JE transactions were completed by the end of June 2023[180][

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Resources Medical Holdings Company Limited 華潤醫療控股有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：1515） 截至2023年12月31日止年度全年業績公告 | --- | --- | --- | |--------------------------------------------------|------------|--------------------| | | | | | 財務摘要 | 2023 年 | 2022 年 （經重列） | | 收益（人民幣千元） | 10,107,500 | 7,901,287 | | 母公司擁有人應佔年度利潤（人民幣千元） | 257,680 | 265,855 | | 母公司普通股權益持有人應佔每股盈利（基本及攤薄） | | | | （人民幣） | 0.20 | 0.21 | | 建議分派 ...

众 華潤醫療控股有限公司 China Resources Medical Holdings Company Limited (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限責任公司) Stock Code 股票代號 : 1515 IN IN IN IN ■■■ E ■ 0 O 中 期 報 告 INTERIM REPORT 2 0 2 3 CONTENTS 目錄 2 Corporate Information 公司資料 5 Management Discussion and Analysis 管理層討論與分析 21 Corporate Governance Highlights 企業管治摘要 24 Other Information 其他資料 32 Review Report 審閱報告 34 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 中期簡明綜合損益及其他全面收益報表 36 In ...